Xiaomei Leng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaomei Leng has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Xiaofeng Zeng
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
17 shared publications Mengtao Li
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
9 shared publicationsFan Yang
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
8 shared publicationsHongbin Li
Department of Rheumatology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
6 shared publicationsHuilan Liu
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC‐DID), Key Laboratory of Rheumatology and Clinical Immunology Ministry of Education Beijing China
6 shared publications- Mengtao Li
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
6 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1937515
Identification of psoriasis-associated hub genes by integrated transcriptomics and machine learning
This study aims to systematically identify key hub genes in psoriasis pathogenesis through the integration of bioinformatics, machine learning and experimental validation methods. Four psoriasis microarray datasets were retrieved from the GEO database, with differentially expressed genes identified through comparative analysis. A dual machine learning approach screened core hub genes, whose expression levels and diagnostic efficacy were validated in an independent cohort. CIBERSORT was employed for immune cell infiltration analysis, whilst a multi-database approach constructed an mRNA-miRNA-lncRNA regulatory network. Molecular docking technology assessed interactions between the environmental pollutant bisphenol A, predicted drugs, and hub genes. Finally, an in vitro psoriasis model was established by stimulating HaCaT cells with the M5 cytokine mixture, with hub gene expression validated via RT-qPCR. Results show that 77 co-differentially expressed genes were identified in psoriasis. Machine learning screened five key hub genes: CARHSP1, HPSE, PCLAF, SERPINB4, and SPRR2C. These were significantly upregulated in the validation cohort and demonstrated strong discriminative value for distinguishing psoriatic lesional skin from paired non-lesional skin, rather than serving as standalone diagnostic biomarkers for psoriasis. Immune cell infiltration analysis revealed extensive associations with immune subpopulations including T cells and macrophages. Molecular docking computationally predicted a potential binding interaction between the environmental pollutant BPA and the hub gene HPSE, which awaits future experimental validation. Concurrently, Genistein and HPSE were suggested a potential interaction that awaits functional validation. In vitro experiments confirmed significant upregulation of HPSE, PCLAF, and SPRR2C mRNA levels in M5-induced psoriasis cell models. HPSE emerged as a multifunctional core gene associated with immune dysregulation. Molecular docking additionally predicted a potential interaction between the environmental pollutant BPA and HPSE; however, this interaction remains a computational hypothesis requiring experimental validation.
- 5 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1937515
Open AccessIdentification of psoriasis-associated hub genes by integrated transcriptomics and machine learning
This study aims to systematically identify key hub genes in psoriasis pathogenesis through the integration of bioinformatics, machine learning and experimental validation methods. Four psoriasis microarray datasets were retrieved from the GEO database, with differentially expressed genes identified through comparative analysis. A dual machine learning approach screened core hub genes, whose expression levels and diagnostic efficacy were validated in an independent cohort. CIBERSORT was employed for immune cell infiltration analysis, whilst a multi-database approach constructed an mRNA-miRNA-lncRNA regulatory network. Molecular docking technology assessed interactions between the environmental pollutant bisphenol A, predicted drugs, and hub genes. Finally, an in vitro psoriasis model was established by stimulating HaCaT cells with the M5 cytokine mixture, with hub gene expression validated via RT-qPCR. Results show that 77 co-differentially expressed genes were identified in psoriasis. Machine learning screened five key hub genes: CARHSP1, HPSE, PCLAF, SERPINB4, and SPRR2C. These were significantly upregulated in the validation cohort and demonstrated strong discriminative value for distinguishing psoriatic lesional skin from paired non-lesional skin, rather than serving as standalone diagnostic biomarkers for psoriasis. Immune cell infiltration analysis revealed extensive associations with immune subpopulations including T cells and macrophages. Molecular docking computationally predicted a potential binding interaction between the environmental pollutant BPA and the hub gene HPSE, which awaits future experimental validation. Concurrently, Genistein and HPSE were suggested a potential interaction that awaits functional validation. In vitro experiments confirmed significant upregulation of HPSE, PCLAF, and SPRR2C mRNA levels in M5-induced psoriasis cell models. HPSE emerged as a multifunctional core gene associated with immune dysregulation. Molecular docking additionally predicted a potential interaction between the environmental pollutant BPA and HPSE; however, this interaction remains a computational hypothesis requiring experimental validation.
- 14 July 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (9) , 5625-5639
Comparative Value of Traditional versus Novel Immune-Inflammatory Indices in Assessing Disease Activity of Sjögren’s Disease: A Multicenter Cohort Study
To evaluate the comparative value of traditional clinical features and novel immune-inflammatory indices in assessing disease activity in primary Sjögren's Disease (SjD), and to construct a robust classification model for moderate-to-severe disease activity using a machine learning approach. This cross-sectional study included 18,738 SjD patients from the Chinese Rheumatism Data Center (CRDC) multicenter prospective cohort. Spearman rank correlation and local polynomial regression (LOESS) were used to explore the relationship between systemic inflammatory indices and the EULAR Sjögren's syndrome disease activity index (ESSDAI). To identify moderate-to-severe disease activity (ESSDAI ≥ 5), data were randomly split into training and validation sets (7:3). Classification models were developed using various machine learning techniques. Higher ESSDAI scores were significantly associated with elevated levels of both traditional markers (ESR, CRP, IgG) and novel composite indices (NLR, CAR, CLR, IBI) (all p < 0.001). However, these indices exhibited only weak-to-moderate linear correlations with ESSDAI and displayed non-linear saturation trends. In multivariable logistic regression, traditional markers remained independent risk factors, whereas all novel composite indices lost statistical significance, yielding a poor validation area under the curve (AUC) of 0.678. Conversely, the XGBoost model demonstrated modestly favorable overall performance Feature importance analysis revealed that patient-reported outcomes, hemoglobin, WBC, age, and IgG were the top contributors to the model, while novel inflammatory indices were completely excluded. Novel immune-inflammatory indices lack provide no independent discriminative value for moderate-to-severe SjD activity when adjusted for traditional parameters. The XGBoost machine learning model effectively handles non-linear variables and highlights the core diagnostic importance of patient-reported outcomes (ESSPRI) and traditional clinical features, providing a favorable evaluation tool. Key Points • Correlation analysis showed that traditional markers (ESR, CRP, IgG) and novel indices (NLR, CAR, CLR, IBI) were significantly associated with higher ESSDAI scores but showed weak-to-moderate linear correlations with nonlinear saturation trends. • In multivariable logistic regression, traditional markers remained independent risk factors, whereas novel indices lost significance. • The XGBoost model outperformed logistic regression and random forest, achieving a validation AUC of 0.701. • Feature importance identified patient-reported outcomes, HB, WBC, age, and IgG as top contributors, while novel indices were excluded.
- 14 July 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (9) , 5625-5639
Comparative Value of Traditional versus Novel Immune-Inflammatory Indices in Assessing Disease Activity of Sjögren’s Disease: A Multicenter Cohort Study
To evaluate the comparative value of traditional clinical features and novel immune-inflammatory indices in assessing disease activity in primary Sjögren's Disease (SjD), and to construct a robust classification model for moderate-to-severe disease activity using a machine learning approach. This cross-sectional study included 18,738 SjD patients from the Chinese Rheumatism Data Center (CRDC) multicenter prospective cohort. Spearman rank correlation and local polynomial regression (LOESS) were used to explore the relationship between systemic inflammatory indices and the EULAR Sjögren's syndrome disease activity index (ESSDAI). To identify moderate-to-severe disease activity (ESSDAI ≥ 5), data were randomly split into training and validation sets (7:3). Classification models were developed using various machine learning techniques. Higher ESSDAI scores were significantly associated with elevated levels of both traditional markers (ESR, CRP, IgG) and novel composite indices (NLR, CAR, CLR, IBI) (all p < 0.001). However, these indices exhibited only weak-to-moderate linear correlations with ESSDAI and displayed non-linear saturation trends. In multivariable logistic regression, traditional markers remained independent risk factors, whereas all novel composite indices lost statistical significance, yielding a poor validation area under the curve (AUC) of 0.678. Conversely, the XGBoost model demonstrated modestly favorable overall performance Feature importance analysis revealed that patient-reported outcomes, hemoglobin, WBC, age, and IgG were the top contributors to the model, while novel inflammatory indices were completely excluded. Novel immune-inflammatory indices lack provide no independent discriminative value for moderate-to-severe SjD activity when adjusted for traditional parameters. The XGBoost machine learning model effectively handles non-linear variables and highlights the core diagnostic importance of patient-reported outcomes (ESSPRI) and traditional clinical features, providing a favorable evaluation tool. Key Points • Correlation analysis showed that traditional markers (ESR, CRP, IgG) and novel indices (NLR, CAR, CLR, IBI) were significantly associated with higher ESSDAI scores but showed weak-to-moderate linear correlations with nonlinear saturation trends. • In multivariable logistic regression, traditional markers remained independent risk factors, whereas novel indices lost significance. • The XGBoost model outperformed logistic regression and random forest, achieving a validation AUC of 0.701. • Feature importance identified patient-reported outcomes, HB, WBC, age, and IgG as top contributors, while novel indices were excluded.
- 13 April 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (6) , 3485-3495
Low-to-moderate dose glucocorticoids in primary Sjögren’s syndrome patients on hydroxychloroquine/iguratimod therapy: a target trial emulation study
Objective To evaluate whether low-to-moderate dose glucocorticoids provide additional benefit in primary Sjögren’s syndrome patients treated with hydroxychloroquine and/or iguratimod. Methods Using the Chinese Rheumatism Data Center database, we emulated a pragmatic trial including 395 patients with primary Sjögren’s syndrome treated between May 2016 and August 2025. All patients received hydroxychloroquine and/or iguratimod as background therapy. Patients were categorized by glucocorticoid use: HCQ/IGU plus glucocorticoid group (≤ 30 mg/day prednisone equivalent, n = 188) or HCQ/IGU group (n = 207). Primary outcome was ESSDAI score change at 1 month. Secondary outcomes included ESSPRI scores and laboratory parameters. Treatment effects were estimated using overlap weighting of propensity scores. Stratified analyses examined subgroups by baseline ESSDAI, IgG levels, and arthritis status. Results After propensity score weighting, baseline characteristics were well-balanced. At 1 month, glucocorticoids provided no additional benefit in ESSDAI change compared to hydroxychloroquine/iguratimod (Cohen’s d = − 0.12; 95% CI, − 0.32 to 0.08; p = 0.270). ESSPRI scores showed no improvement (Cohen’s d = − 0.20; 95% CI, − 0.39 to 0.00; p = 0.077). While glucocorticoids increased white blood cell counts (Cohen’s d = 0.57; p < 0.001) and decreased IgG levels (Cohen’s d = − 0.33; p = 0.004), these changes did not translate into clinical benefits. Stratified analyses revealed no additional benefit from glucocorticoids in any subgroup, including patients with higher disease activity (ESSDAI ≥ 5), elevated IgG, or arthritis. Conclusion Low-to-moderate dose glucocorticoids (≤ 30 mg/day prednisone equivalent) provide no additional short-term clinical benefit at 1-month follow-up in primary Sjögren’s syndrome patients receiving background hydroxychloroquine and/or iguratimod therapy. Key Points • Low-to-Moderate dose glucocorticoids show no additional benefit over hydroxychloroquine/iguratimod therapy in primary Sjögren's syndrome patients.
- 13 April 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (6) , 3485-3495
Low-to-moderate dose glucocorticoids in primary Sjögren’s syndrome patients on hydroxychloroquine/iguratimod therapy: a target trial emulation study
Objective To evaluate whether low-to-moderate dose glucocorticoids provide additional benefit in primary Sjögren’s syndrome patients treated with hydroxychloroquine and/or iguratimod. Methods Using the Chinese Rheumatism Data Center database, we emulated a pragmatic trial including 395 patients with primary Sjögren’s syndrome treated between May 2016 and August 2025. All patients received hydroxychloroquine and/or iguratimod as background therapy. Patients were categorized by glucocorticoid use: HCQ/IGU plus glucocorticoid group (≤ 30 mg/day prednisone equivalent, n = 188) or HCQ/IGU group (n = 207). Primary outcome was ESSDAI score change at 1 month. Secondary outcomes included ESSPRI scores and laboratory parameters. Treatment effects were estimated using overlap weighting of propensity scores. Stratified analyses examined subgroups by baseline ESSDAI, IgG levels, and arthritis status. Results After propensity score weighting, baseline characteristics were well-balanced. At 1 month, glucocorticoids provided no additional benefit in ESSDAI change compared to hydroxychloroquine/iguratimod (Cohen’s d = − 0.12; 95% CI, − 0.32 to 0.08; p = 0.270). ESSPRI scores showed no improvement (Cohen’s d = − 0.20; 95% CI, − 0.39 to 0.00; p = 0.077). While glucocorticoids increased white blood cell counts (Cohen’s d = 0.57; p < 0.001) and decreased IgG levels (Cohen’s d = − 0.33; p = 0.004), these changes did not translate into clinical benefits. Stratified analyses revealed no additional benefit from glucocorticoids in any subgroup, including patients with higher disease activity (ESSDAI ≥ 5), elevated IgG, or arthritis. Conclusion Low-to-moderate dose glucocorticoids (≤ 30 mg/day prednisone equivalent) provide no additional short-term clinical benefit at 1-month follow-up in primary Sjögren’s syndrome patients receiving background hydroxychloroquine and/or iguratimod therapy. Key Points • Low-to-Moderate dose glucocorticoids show no additional benefit over hydroxychloroquine/iguratimod therapy in primary Sjögren's syndrome patients.
- 3 March 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (5) , 2703-2719
Exploring clinical subtypes of Chinese patients with psoriatic arthritis based on cluster analysis: a national registry study (CREPAR V)
Objective This study aimed to identify distinct clinical phenotypes within a Chinese cohort of patients with psoriatic arthritis (PsA). Methods A total of 1074 patient data were analyzed from the Chinese Psoriatic Arthritis Registry (CREPAR). A two-step clustering approach was used to identify patient subtypes based on the unsupervised clustering of baseline clinical characteristics. Kaplan–Meier curves were used to compare long-term remission probabilities across subtypes, and Cox proportional hazards regression models were used to identify independent risk factors. Results The cluster analysis identified three subtypes of patients with distinct clinical presentations, laboratory tests, and prognoses. Cluster 1 patients presented with the most extensive and intense polyarticular inflammation, accompanied by a 'concentrated-severe' pattern of dactylitis across multiple sites. Patients in Cluster 2 had the least peripheral joint involvement, with an extremely low incidence of dactylitis (0.8%). Cluster 3 is characterised by dactylitis in almost all patients (98.9%), presenting a extensive pattern with moderate frequency across sites, alongside common peripheral arthritis. A survival analysis revealed highly significant differences between subtypes in the probability curves for non-remission. Across all subtypes, the Cox regression identified the following independent risk factors: a later age at onset of arthritis, a longer duration of psoriasis, and high baseline DAPSA scores. Conclusion The purpose of this study is to establish a clinical risk framework for Chinese PsA patients. Identification of high-risk patients based on specific joint/dactylitis patterns is crucial to guiding intensive treatment. Key Points • Three clinical subtypes of psoriatic arthritis with significant heterogeneity were identified in this study: including a refractory type characterised by systemic hyperinflammation and severe multi-joint involvement (Cluster 1), a mild type with predominantly mild axial involvement and mild symptoms (Cluster 2), and a widespread dactylitis type with near-universal dactylitis as the core manifestation (Cluster 3). • The subtypes differ fundamentally in the specific pattern of involvement of peripheral joints with dactylitis, which provides a key phenotypic basis for subtype differentiation and directly correlates to very different probabilities of long-term remission. • Later age at onset of arthritis, longer duration of psoriasis, and high disease activity are common prognostic risk factors across subtypes, underscoring the clinical necessity of early and intensive treatment of high-risk subtypes to improve long-term outcomes.
- 3 March 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (5) , 2703-2719
Exploring clinical subtypes of Chinese patients with psoriatic arthritis based on cluster analysis: a national registry study (CREPAR V)
Objective This study aimed to identify distinct clinical phenotypes within a Chinese cohort of patients with psoriatic arthritis (PsA). Methods A total of 1074 patient data were analyzed from the Chinese Psoriatic Arthritis Registry (CREPAR). A two-step clustering approach was used to identify patient subtypes based on the unsupervised clustering of baseline clinical characteristics. Kaplan–Meier curves were used to compare long-term remission probabilities across subtypes, and Cox proportional hazards regression models were used to identify independent risk factors. Results The cluster analysis identified three subtypes of patients with distinct clinical presentations, laboratory tests, and prognoses. Cluster 1 patients presented with the most extensive and intense polyarticular inflammation, accompanied by a 'concentrated-severe' pattern of dactylitis across multiple sites. Patients in Cluster 2 had the least peripheral joint involvement, with an extremely low incidence of dactylitis (0.8%). Cluster 3 is characterised by dactylitis in almost all patients (98.9%), presenting a extensive pattern with moderate frequency across sites, alongside common peripheral arthritis. A survival analysis revealed highly significant differences between subtypes in the probability curves for non-remission. Across all subtypes, the Cox regression identified the following independent risk factors: a later age at onset of arthritis, a longer duration of psoriasis, and high baseline DAPSA scores. Conclusion The purpose of this study is to establish a clinical risk framework for Chinese PsA patients. Identification of high-risk patients based on specific joint/dactylitis patterns is crucial to guiding intensive treatment. Key Points • Three clinical subtypes of psoriatic arthritis with significant heterogeneity were identified in this study: including a refractory type characterised by systemic hyperinflammation and severe multi-joint involvement (Cluster 1), a mild type with predominantly mild axial involvement and mild symptoms (Cluster 2), and a widespread dactylitis type with near-universal dactylitis as the core manifestation (Cluster 3). • The subtypes differ fundamentally in the specific pattern of involvement of peripheral joints with dactylitis, which provides a key phenotypic basis for subtype differentiation and directly correlates to very different probabilities of long-term remission. • Later age at onset of arthritis, longer duration of psoriasis, and high disease activity are common prognostic risk factors across subtypes, underscoring the clinical necessity of early and intensive treatment of high-risk subtypes to improve long-term outcomes.
- 21 January 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (3) , 1753-1763
Risk factors for disease progression in primary Sjögren's syndrome patients with low disease activity: a multicenter registry-based cohort study
Background and Objectives Primary Sjögren's syndrome (pSS) patients with low disease activity remain at risk for disease progression, yet predictive factors are poorly understood. We aimed to identify risk factors for disease worsening in pSS patients with initially low disease activity. Methods We conducted a registry-based cohort study using prospectively collected data from the Chinese Rheumatism Data Center (CRDC). Patients with pSS meeting either 2002 AECG or 2016 ACR/EULAR classification criteria and baseline ESSDAI < 5 were included. Disease worsening was defined as ESSDAI increase ≥ 3 points during follow-up. Cox proportional hazards regression with LASSO selection identified independent risk factors. Results Among 745 patients (median age 46 years, 97.4% female), 214 (28.7%) experienced disease worsening during median follow-up of 36 months. Univariate analysis and LASSO regression selected 11 variables for multivariate analysis. Independent risk factors were renal involvement (HR = 6.18, 95%CI: 2.44–15.61, P < 0.001), anti-Sm positivity (HR = 2.10, 95%CI: 1.12–3.93, P = 0.020), and dry eye symptoms (HR = 1.46, 95%CI: 1.06–2.00, P = 0.022). Conclusions Nearly one-third of pSS patients with low disease activity experience disease worsening. Renal involvement, anti-Sm antibodies, and dry eye symptoms independently predict progression. Risk stratification based on these factors can identify patients requiring closer monitoring and potentially more intensive therapeutic intervention. Key Points • This multicenter registry study of 745 primary Sjögren's syndrome patients with low disease activity found that 28.7% experienced disease worsening during follow-up, highlighting that low disease activity does not guarantee disease stability. • Three independent predictors of disease progression were identified: renal involvement (HR = 6.18), anti-Sm antibody positivity (HR = 2.10), and dry eye symptoms (HR = 1.46). • Conventional synthetic DMARDs were not significantly associated with reduced disease worsening in adjusted models, highlighting the need for randomized trials to properly evaluate therapeutic strategies.
- 21 January 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (3) , 1753-1763
Risk factors for disease progression in primary Sjögren's syndrome patients with low disease activity: a multicenter registry-based cohort study
Background and Objectives Primary Sjögren's syndrome (pSS) patients with low disease activity remain at risk for disease progression, yet predictive factors are poorly understood. We aimed to identify risk factors for disease worsening in pSS patients with initially low disease activity. Methods We conducted a registry-based cohort study using prospectively collected data from the Chinese Rheumatism Data Center (CRDC). Patients with pSS meeting either 2002 AECG or 2016 ACR/EULAR classification criteria and baseline ESSDAI < 5 were included. Disease worsening was defined as ESSDAI increase ≥ 3 points during follow-up. Cox proportional hazards regression with LASSO selection identified independent risk factors. Results Among 745 patients (median age 46 years, 97.4% female), 214 (28.7%) experienced disease worsening during median follow-up of 36 months. Univariate analysis and LASSO regression selected 11 variables for multivariate analysis. Independent risk factors were renal involvement (HR = 6.18, 95%CI: 2.44–15.61, P < 0.001), anti-Sm positivity (HR = 2.10, 95%CI: 1.12–3.93, P = 0.020), and dry eye symptoms (HR = 1.46, 95%CI: 1.06–2.00, P = 0.022). Conclusions Nearly one-third of pSS patients with low disease activity experience disease worsening. Renal involvement, anti-Sm antibodies, and dry eye symptoms independently predict progression. Risk stratification based on these factors can identify patients requiring closer monitoring and potentially more intensive therapeutic intervention. Key Points • This multicenter registry study of 745 primary Sjögren's syndrome patients with low disease activity found that 28.7% experienced disease worsening during follow-up, highlighting that low disease activity does not guarantee disease stability. • Three independent predictors of disease progression were identified: renal involvement (HR = 6.18), anti-Sm antibody positivity (HR = 2.10), and dry eye symptoms (HR = 1.46). • Conventional synthetic DMARDs were not significantly associated with reduced disease worsening in adjusted models, highlighting the need for randomized trials to properly evaluate therapeutic strategies.
- Open Access
- 20 August 2025
- Published by World Scientific Pub Co Pte Ltd in Journal of Innovative Optical Health Sciences
- Vol. 19 (01)
Oxygenation-driven multimodal photoacoustic/ultrasonic imaging enhances evaluation of enthesitis disease activity in psoriatic arthritis
Conventional ultrasound (US) evaluation of enthesitis in psoriatic arthritis (PsA) is limited by its inability to quantify metabolic alterations such as hypoxia, a key driver of disease activity. We introduce an oxygenation-integrated multimodal photoacoustic/ultrasound (PA/US) imaging framework designed to quantify entheseal oxygen saturation (SO 2 ) for assessing entheseal disease activity in PsA. In this cross-sectional study, 25 PsA patients underwent bilateral PA/US imaging of 12 entheses, where ultrasound lesions were scored using the Outcome Measures in Rheumatology scoring system, and PA-derived SO 2 levels, quantified via dual-wavelength PA imaging, were classified into hyperoxia or hypoxia groups using k-means clustering. This approach provides metabolic insights complementary to conventional ultrasonic assessment. A composite score integrating hypoxia with US parameters was validated against clinical disease activity indices (Disease Activity Score 28-C-reactive protein, DAS28-CRP; Disease Activity Index for Psoriatic Arthritis, DAPSA). Among 300 entheses, 103 (34.3%) exhibited PA positivity, with 40 (38.8%) classified as hypoxia. Hypoxia scores independently predicted DAS28-CRP ([ ] = 0.618, p = 0.001) and DAPSA ([ ] = 0.612, [ ]). The hypoxia-optimized PAUS score demonstrated superior correlation with disease activity indices compared to conventional US (DAS28-CRP: r = 0.615, p = 0.001 versus r = 0.474, p = 0.017; DAPSA: r = 0.743, [ ] versus r = 0.567, p = 0.003), alongside superior diagnostic accuracy for minimal disease activity (area under the curve, AUC 0.776 versus 0.614, p = 0.008) and low disease activity (AUC 0.853 versus 0.772, p = 0.009). This multimodal scoring system enhances the stratification of PsA disease activity by providing unique metabolic insights, offering a potential tool for therapeutic monitoring and guiding treat-to-target strategies.
- 20 August 2025
- Published by World Scientific Pub Co Pte Ltd in Journal of Innovative Optical Health Sciences
- Vol. 19 (01)
Open AccessOxygenation-driven multimodal photoacoustic/ultrasonic imaging enhances evaluation of enthesitis disease activity in psoriatic arthritis
Conventional ultrasound (US) evaluation of enthesitis in psoriatic arthritis (PsA) is limited by its inability to quantify metabolic alterations such as hypoxia, a key driver of disease activity. We introduce an oxygenation-integrated multimodal photoacoustic/ultrasound (PA/US) imaging framework designed to quantify entheseal oxygen saturation (SO 2 ) for assessing entheseal disease activity in PsA. In this cross-sectional study, 25 PsA patients underwent bilateral PA/US imaging of 12 entheses, where ultrasound lesions were scored using the Outcome Measures in Rheumatology scoring system, and PA-derived SO 2 levels, quantified via dual-wavelength PA imaging, were classified into hyperoxia or hypoxia groups using k-means clustering. This approach provides metabolic insights complementary to conventional ultrasonic assessment. A composite score integrating hypoxia with US parameters was validated against clinical disease activity indices (Disease Activity Score 28-C-reactive protein, DAS28-CRP; Disease Activity Index for Psoriatic Arthritis, DAPSA). Among 300 entheses, 103 (34.3%) exhibited PA positivity, with 40 (38.8%) classified as hypoxia. Hypoxia scores independently predicted DAS28-CRP ([ ] = 0.618, p = 0.001) and DAPSA ([ ] = 0.612, [ ]). The hypoxia-optimized PAUS score demonstrated superior correlation with disease activity indices compared to conventional US (DAS28-CRP: r = 0.615, p = 0.001 versus r = 0.474, p = 0.017; DAPSA: r = 0.743, [ ] versus r = 0.567, p = 0.003), alongside superior diagnostic accuracy for minimal disease activity (area under the curve, AUC 0.776 versus 0.614, p = 0.008) and low disease activity (AUC 0.853 versus 0.772, p = 0.009). This multimodal scoring system enhances the stratification of PsA disease activity by providing unique metabolic insights, offering a potential tool for therapeutic monitoring and guiding treat-to-target strategies.
- Open Access
- 8 April 2025
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 12 (3) , 529-546
A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product
Introduction Biosimilars need to demonstrate similarity in terms of quality, pharmacokinetics (PK), efficacy, safety, and immunogenicity. Here, we report the outcome of a comprehensive evaluation of the immunogenicity of the biosimilar BAT1806 compared with the tocilizumab reference product (TCZ). Methods We conducted a post hoc analysis of study BAT1806-001-CR, a comparative PK study in healthy male volunteers (n = 129), and BAT1806-002-CR, a phase III, 52-week trial in patients with rheumatoid arthritis (n = 621). Anti-drug antibodies (ADA), ADA titers, and neutralizing ADA were measured, and their impact on PK, safety, and efficacy parameters were assessed. Results In BAT1806-001-CR, treatment-induced ADA were observed in 37.8% of participants for the BAT1806 group, 28.6% for the EU-sourced TCZ group, and 31.0% for the US-sourced TCZ group, without an impact on PK and safety. In BAT1806-002-CR after 52 weeks, 28.2% of participants in the BAT1806 group developed treatment-induced ADA, compared with 24.0% in the TCZ group and 19.7% of participants who initiated TCZ and switched to BAT1806 at week 24. ADA-positive participants reported lower geometric mean serum tocilizumab trough concentrations than ADA-negative participants in all treatment groups. ADA-positive participants achieved similar efficacy outcomes to ADA-negative participants in all treatment groups. ADA were not associated with an incremental risk of treatment-emergent adverse events or hypersensitivity in any of the treatment groups. Conclusions The results of these post hoc analyses did not indicate any clinically relevant differences in the immunogenicity profile of intravenously administered BAT1806 compared with TCZ. Trial registration ClinicalTrials.gov identifiers, NCT03606876, NCT03830203.
- 8 April 2025
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 12 (3) , 529-546
Open AccessA Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product
Introduction Biosimilars need to demonstrate similarity in terms of quality, pharmacokinetics (PK), efficacy, safety, and immunogenicity. Here, we report the outcome of a comprehensive evaluation of the immunogenicity of the biosimilar BAT1806 compared with the tocilizumab reference product (TCZ). Methods We conducted a post hoc analysis of study BAT1806-001-CR, a comparative PK study in healthy male volunteers (n = 129), and BAT1806-002-CR, a phase III, 52-week trial in patients with rheumatoid arthritis (n = 621). Anti-drug antibodies (ADA), ADA titers, and neutralizing ADA were measured, and their impact on PK, safety, and efficacy parameters were assessed. Results In BAT1806-001-CR, treatment-induced ADA were observed in 37.8% of participants for the BAT1806 group, 28.6% for the EU-sourced TCZ group, and 31.0% for the US-sourced TCZ group, without an impact on PK and safety. In BAT1806-002-CR after 52 weeks, 28.2% of participants in the BAT1806 group developed treatment-induced ADA, compared with 24.0% in the TCZ group and 19.7% of participants who initiated TCZ and switched to BAT1806 at week 24. ADA-positive participants reported lower geometric mean serum tocilizumab trough concentrations than ADA-negative participants in all treatment groups. ADA-positive participants achieved similar efficacy outcomes to ADA-negative participants in all treatment groups. ADA were not associated with an incremental risk of treatment-emergent adverse events or hypersensitivity in any of the treatment groups. Conclusions The results of these post hoc analyses did not indicate any clinically relevant differences in the immunogenicity profile of intravenously administered BAT1806 compared with TCZ. Trial registration ClinicalTrials.gov identifiers, NCT03606876, NCT03830203.
- Open Access
- 22 November 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 2575-2582
68Ga-FAPI and 18F-NaF PET/CT in psoriatic arthritis: a comparative study
As fibroblast-like synoviocyte activation and bone formation are associated with psoriatic arthritis (PsA), positron emission tomography (PET) using the tracers of 68Ga-fibroblast activation protein inhibitor (FAPI) and 18F-sodium fluoride (NaF) may sensitively detect the disease. In this prospective study, we aimed to evaluate the performance of 68Ga-FAPI PET/CT in PsA and to compare it with 18F-NaF PET/CT. Sixteen participants (female 7/16, age 42.31 ± 10.66 years) with PsA were prospectively enrolled and underwent dual-tracer PET/CT, clinical assessment and ultrasonography. PET/CT images were scored for PET-positive lesions at the peripheral joints, entheses, and axial joints. The positivity rate of 68Ga-FAPI in peripheral joints is higher than that in entheses and axial joints (21.84% vs 12.15% vs 0%), whereas high positivity rates of 18F-NaF in peripheral joints, entheses, and axial joints were observed (85.23%, 78.13%, and 75%, respectively). The disease activity score 28 was higher in the PET-positive than in the PET-negative group with 68Ga-FAPI (5.25 ± 1.84 vs 2.55 ± 0.94, p= 0.037), but not with 18F-NaF. Besides, the PET joint count at 68Ga-FAPI PET/CT was positively correlated with the TJC (r = 0.604, p= 0.017), SJC (r = 0.773, p= 0.001), DAS28-CRP (r = 0.556, p= 0.032), PASDAS (r = 0.540, p= 0.038) and PsASon13 (r = 0.701, p= 0.005), while no correlation was observed in 18F-NaF PET/CT. The positivity rates of 68Ga-FAPI- and 18F-NaF PET/CT were different in patients with PsA in peripheral joints, entheses, and axial joints. The extent of joint involvement at 68Ga-FAPI PET/CT correlated with clinical and ultrasound variables as well as disease activity.
- 22 November 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 2575-2582
Open Access68Ga-FAPI and 18F-NaF PET/CT in psoriatic arthritis: a comparative study
As fibroblast-like synoviocyte activation and bone formation are associated with psoriatic arthritis (PsA), positron emission tomography (PET) using the tracers of 68Ga-fibroblast activation protein inhibitor (FAPI) and 18F-sodium fluoride (NaF) may sensitively detect the disease. In this prospective study, we aimed to evaluate the performance of 68Ga-FAPI PET/CT in PsA and to compare it with 18F-NaF PET/CT. Sixteen participants (female 7/16, age 42.31 ± 10.66 years) with PsA were prospectively enrolled and underwent dual-tracer PET/CT, clinical assessment and ultrasonography. PET/CT images were scored for PET-positive lesions at the peripheral joints, entheses, and axial joints. The positivity rate of 68Ga-FAPI in peripheral joints is higher than that in entheses and axial joints (21.84% vs 12.15% vs 0%), whereas high positivity rates of 18F-NaF in peripheral joints, entheses, and axial joints were observed (85.23%, 78.13%, and 75%, respectively). The disease activity score 28 was higher in the PET-positive than in the PET-negative group with 68Ga-FAPI (5.25 ± 1.84 vs 2.55 ± 0.94, p= 0.037), but not with 18F-NaF. Besides, the PET joint count at 68Ga-FAPI PET/CT was positively correlated with the TJC (r = 0.604, p= 0.017), SJC (r = 0.773, p= 0.001), DAS28-CRP (r = 0.556, p= 0.032), PASDAS (r = 0.540, p= 0.038) and PsASon13 (r = 0.701, p= 0.005), while no correlation was observed in 18F-NaF PET/CT. The positivity rates of 68Ga-FAPI- and 18F-NaF PET/CT were different in patients with PsA in peripheral joints, entheses, and axial joints. The extent of joint involvement at 68Ga-FAPI PET/CT correlated with clinical and ultrasound variables as well as disease activity.
- Open Access
- 22 August 2024
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 12 (8) , e1362
Belimumab in early systemic lupus erythematosus: A propensity score matching analysis
Objective: This study aimed to evaluate the clinical efficacy of belimumab in patients with early systemic lupus erythematosus (SLE), defined as having a disease duration of less than 6 months.Methods: We retrospectively identified patients with SLE in the early stage who received belimumab and standard of care (belimumab group) or standard of care alone (control group) since September 2020. Propensity score matching (PSM) was used to reduce potential bias. The primary endpoint was lupus low disease activity status (LLDAS) at weeks 12 and 24. The secondary endpoints were remission and the proportion of glucocorticoid dose tapering to 7.5 mg/day. The efficacy of belimumab in patients with lupus nephritis was also assessed.Results: Out of 111 eligible patients, 16 patients in the belimumab group and 31 patients in the control group were identified by 1:2 PSM. At week 24, a significantly higher proportion of individuals achieved low disease activity state (LLDAS) in the belimumab group compared to the control group (56.3% vs. 19.4%, OR = 5.357, 95% CI = 1.417 to 20.260, p = 0.013). Furthermore, more patients in the belimumab group were reduced to low‐dose glucocorticoid ( ≤ 7.5 mg/day) at week 24 (75.0% vs. 35.5%, OR = 5.182, 95%CI = 1.339 to 20.058, p = 0.017). Significant improvements in Patient Global Assessment scores were observed at Week 12 and 24 for those treated with belimumab compared to controls. In a subgroup analysis evaluating the efficacy of belimumab in patients with lupus nephritis, 42.9% of the seven individuals treated with belimumab achieved a complete renal response (CRR) by Week 24, and no instances of disease relapse were observed.Conclusions: In SLE patients with a disease duration of less than 6 months, belimumab treatment can promote LLDAS achievement and reduce glucocorticoid dose, leading to a better prognosis. Introducing belimumab in the early stage of SLE may be a beneficial decision.
- 22 August 2024
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 12 (8) , e1362
Open AccessBelimumab in early systemic lupus erythematosus: A propensity score matching analysis
Objective: This study aimed to evaluate the clinical efficacy of belimumab in patients with early systemic lupus erythematosus (SLE), defined as having a disease duration of less than 6 months.Methods: We retrospectively identified patients with SLE in the early stage who received belimumab and standard of care (belimumab group) or standard of care alone (control group) since September 2020. Propensity score matching (PSM) was used to reduce potential bias. The primary endpoint was lupus low disease activity status (LLDAS) at weeks 12 and 24. The secondary endpoints were remission and the proportion of glucocorticoid dose tapering to 7.5 mg/day. The efficacy of belimumab in patients with lupus nephritis was also assessed.Results: Out of 111 eligible patients, 16 patients in the belimumab group and 31 patients in the control group were identified by 1:2 PSM. At week 24, a significantly higher proportion of individuals achieved low disease activity state (LLDAS) in the belimumab group compared to the control group (56.3% vs. 19.4%, OR = 5.357, 95% CI = 1.417 to 20.260, p = 0.013). Furthermore, more patients in the belimumab group were reduced to low‐dose glucocorticoid ( ≤ 7.5 mg/day) at week 24 (75.0% vs. 35.5%, OR = 5.182, 95%CI = 1.339 to 20.058, p = 0.017). Significant improvements in Patient Global Assessment scores were observed at Week 12 and 24 for those treated with belimumab compared to controls. In a subgroup analysis evaluating the efficacy of belimumab in patients with lupus nephritis, 42.9% of the seven individuals treated with belimumab achieved a complete renal response (CRR) by Week 24, and no instances of disease relapse were observed.Conclusions: In SLE patients with a disease duration of less than 6 months, belimumab treatment can promote LLDAS achievement and reduce glucocorticoid dose, leading to a better prognosis. Introducing belimumab in the early stage of SLE may be a beneficial decision.
- Open Access
- 1 March 2024
- Published by Springer Nature in European Journal of Medical Research
- Vol. 29 (1) , 1-11
Serum proteome analysis identifies a potential biomarker for axial psoriatic arthritis
To identify potential serum biomarkers for differentiating between axial psoriatic arthritis (axPsA) and peripheral psoriatic arthritis (pPsA). Serum samples were collected from patients with PsA to create a biomarker discovery cohort and a verification cohort. Patients with PsA were classified into axial or peripheral subtypes based on imaging criteria. Untargeted proteomics technology was used in the discovery phase to screen for biomarkers, and candidate biomarkers were evaluated using enzyme-linked immunosorbent assay (ELISA) in the verification phase. We identified 45 significantly differentially expressed proteins (DEPs) between axPsA (n = 20) and pPsA (n = 20) with liquid chromatography-mass spectrometry. Among these DEPs, serum pigment epithelium-derived factor (PEDF) was identified as a candidate biomarker using the Boruta algorithm and lasso regression. Results of ELISA further confirmed that the level of serum PEDF expression was significantly higher in axPsA (n = 37) than in pPsA (n = 51) at the verification cohort (37.9 ± 10.1 vs. 30.5 ± 8.9 μg/mL, p < 0.001). Receiver operating characteristics analysis showed that PEDF had an area under the curve (AUC) of 0.72. Serum PEDF was positively correlated with body mass index and C-reactive protein. Additionally, there was a tendency towards a positive correlation between PEDF and the Bath Ankylosing Spondylitis Disease Activity Index. This study provided a comprehensive characterization of the proteome in axPsA and pPsA and identified a candidate biomarker, PEDF, that may contribute to early diagnosis for axPsA.
- 1 March 2024
- Published by Springer Nature in European Journal of Medical Research
- Vol. 29 (1) , 1-11
Open AccessSerum proteome analysis identifies a potential biomarker for axial psoriatic arthritis
To identify potential serum biomarkers for differentiating between axial psoriatic arthritis (axPsA) and peripheral psoriatic arthritis (pPsA). Serum samples were collected from patients with PsA to create a biomarker discovery cohort and a verification cohort. Patients with PsA were classified into axial or peripheral subtypes based on imaging criteria. Untargeted proteomics technology was used in the discovery phase to screen for biomarkers, and candidate biomarkers were evaluated using enzyme-linked immunosorbent assay (ELISA) in the verification phase. We identified 45 significantly differentially expressed proteins (DEPs) between axPsA (n = 20) and pPsA (n = 20) with liquid chromatography-mass spectrometry. Among these DEPs, serum pigment epithelium-derived factor (PEDF) was identified as a candidate biomarker using the Boruta algorithm and lasso regression. Results of ELISA further confirmed that the level of serum PEDF expression was significantly higher in axPsA (n = 37) than in pPsA (n = 51) at the verification cohort (37.9 ± 10.1 vs. 30.5 ± 8.9 μg/mL, p < 0.001). Receiver operating characteristics analysis showed that PEDF had an area under the curve (AUC) of 0.72. Serum PEDF was positively correlated with body mass index and C-reactive protein. Additionally, there was a tendency towards a positive correlation between PEDF and the Bath Ankylosing Spondylitis Disease Activity Index. This study provided a comprehensive characterization of the proteome in axPsA and pPsA and identified a candidate biomarker, PEDF, that may contribute to early diagnosis for axPsA.